<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03126149</url>
  </required_header>
  <id_info>
    <org_study_id>C0231002</org_study_id>
    <secondary_id>2017-000590-36</secondary_id>
    <nct_id>NCT03126149</nct_id>
  </id_info>
  <brief_title>First in Human Study for PF-06667272</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind (Sponsor-open), Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06667272 Under Fed And Fasted Conditions, In Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is the first clinical trial proposed with PF-06667272. It is designed to
      evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending doses of
      PF-06667272 under fed and fasted conditions, in healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 11, 2017</start_date>
  <completion_date type="Actual">September 5, 2017</completion_date>
  <primary_completion_date type="Actual">September 5, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Treatment Emergent Treatment-Related Adverse Events (AEs) or other safety concerns</measure>
    <time_frame>Baseline (Day 1, hour 0) up to 28 days after last dose of study medication</time_frame>
    <description>Assessment by adverse event monitoring, 12 lead ECGs, telemetry, vital signs and clinical safety laboratory measurements.
Treatment-related AE was any untoward medical occurrence attributed to study drug in a subject who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Drug was assessed by the investigator (Yes/No). Subjects with multiple occurrences of an AE within a category were counted once within the category.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06667272 and PF-06818073</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post dose</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0- infinity)] for PF-06667272 and PF-06818073 (as permitted)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post dose</time_frame>
    <description>AUC (0-infinity)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-infinity). It is obtained from AUC (0-t) plus AUC (t-infinity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for PF-06667272 and PF-06818073</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post dose</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration for PF-06667272 and PF-06818073</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post dose</time_frame>
    <description>Time to Reach Maximum Observed Plasma Concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for PF-06667272 and PF-06818073</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post dose</time_frame>
    <description>Plasma Decay Half-Life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance (CL/F) for PF-06667272</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post dose</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after apparent total body clearance is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) for PF-06667272</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post dose</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1_Period 1_Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of PF-06667272</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1_Period 1_Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1_Period 2_Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of PF-06667272</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1_Period 2_Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1_Period 3_Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of PF-06667272</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1_Period 3_Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohrot 1_Period 4_Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of PF-06667272</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1_Period 4_Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2_Period 1_Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of PF-06667272</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2_Period 1_Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2_Period 2_Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of PF-06667272</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2_Period 2_Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2_Period 3_Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of PF-06667272</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2_Period 3_Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2_Period 4_Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of PF-06667272</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2_Period 4_Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06667272</intervention_name>
    <description>Single ascending dose of PF-06667272</description>
    <arm_group_label>Cohort 1_Period 1_Active</arm_group_label>
    <arm_group_label>Cohort 1_Period 2_Active</arm_group_label>
    <arm_group_label>Cohort 1_Period 3_Active</arm_group_label>
    <arm_group_label>Cohrot 1_Period 4_Active</arm_group_label>
    <arm_group_label>Cohort 2_Period 1_Active</arm_group_label>
    <arm_group_label>Cohort 2_Period 2_Active</arm_group_label>
    <arm_group_label>Cohort 2_Period 3_Active</arm_group_label>
    <arm_group_label>Cohort 2_Period 4_Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of placebo</description>
    <arm_group_label>Cohort 1_Period 1_Placebo</arm_group_label>
    <arm_group_label>Cohort 1_Period 2_Placebo</arm_group_label>
    <arm_group_label>Cohort 1_Period 3_Placebo</arm_group_label>
    <arm_group_label>Cohort 1_Period 4_Placebo</arm_group_label>
    <arm_group_label>Cohort 2_Period 1_Placebo</arm_group_label>
    <arm_group_label>Cohort 2_Period 2_Placebo</arm_group_label>
    <arm_group_label>Cohort 2_Period 3_Placebo</arm_group_label>
    <arm_group_label>Cohort 2_Period 4_Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and female of non-childbearing potential;

          -  Body Mass Index 17.5-30.5 kg/m2;

          -  Body weight &gt;50 kg;

        Exclusion Criteria:

          -  Evidence of history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C0231002&amp;StudyName=A+Phase+1%2C+Randomized%2C+Double-blind+%28sponsor-open%29%2C+Placebo-controlled+Study+To+Assess+The+Safety%2C+Tolerability%2C+And+Pharmacokinetics+Of+Single+Escalating+Oral+Doses+Of+Pf-06667272+Under+Fed+And+Fasted+Conditions%2C+In+Healthy+Adult+Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

